LTR Pharma secures a 33pc stake in new omega-3 venture LevOmega

• LTR Pharma co-founds and secures 33% ownership in LevOmega
• New company to focus on developing nature-identical omega-3 products
• Provides LTR with exposure to lucrative multi-billion market omega-3 market

Special Report: LTR Pharma has co-founded and secured a 33% equity ownership in LevOmega, an Australian company focused on development of nature-identical omega-3 products.

LevOmega has been co-founded by Levur, Green Blue Health and LTR Pharma (ASX:LTP), with a mission to deliver high-purity, consistent omega-3 ingredients that can be used in both nutritional and pharmaceutical applications.

Each co-founding company brings strengths to the table with Levur in innovation and product development, Green Blue Health in nutraceutical and health market experience, and LTR Pharma in pharmaceutical, regulatory and commercial capability.

LTR Pharma said ownership recognised the company’s leadership and commercial expertise, with no upfront capital required and nil cost to shareholders for the one-third stake.

The company said for investors, the structure ensures LTR Pharma can participate in a high-growth market opportunity as another first-in-class product.

Growing demand for omega-3

By combining expertise in biotechnology, formulation, and pharmaceutical development, LevOmega aims to meet the growing global demand for sustainable and clinically validated omega-3 solutions.

Omega-3 oil is widely recognised for its cardiovascular and anti-inflammatory health benefits.

However, LTR said the current reliance on marine harvesting to meet demand is under increasing strain due to overfishing, pollution and declining yields.

Studies note that global nutritional requirements for eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) already exceed sustainable marine supply, and environmental changes continue to affect quality and consistency.

As a result, demand for nature-identical omega-3 products is expected to rise sharply.

Traditional fish oil sources are becoming less reliable and consistent due to worsening global ocean conditions, underscoring the need for scalable, sustainable alternatives.

LevOmega to start development journey

LevOmega has signed an R&D services and licensing deal with Levur, marking the start of its development program and a key milestone for the new company and its shareholders.

Under the agreement, Levur will provide specialist R&D services and license its proprietary biotechnology platform to support LevOmega’s development of nature-identical, pharmaceutical-grade omega-3 oil.

LTR said LevOmega’s development pathway would progress through technical validation, pilot-scale production and ultimately commercial launch, supplying pharmaceutical-grade omega-3 ingredients to pharmaceutical, nutraceutical and functional food manufacturers

Alignment with LTR’s growth strategy

LTR Pharma continues to grow its products and pipeline as it looks to unlock value for shareholders, leveraging its ability to develop first-in-class products for large healthcare markets.

The company said its latest venture provides LTR with exposure to the multi-billion-dollar global omega-3 market and is complementary to its core intranasal pharmaceutical programs.

The company’s flagship products Spontan along with Roxus are first-in-class, rapid-acting nasal sprays for erectile dysfunction.

LTR Pharma is also developing Oroflow, a novel treatment for oesophageal motility disorders.

Executive chairman Lee Rodne said LevOmega highlighted its ability to identify and secure transformative opportunities in large healthcare markets.

“The omega-3 sector is a multi-billion-dollar market facing supply constraints, and LevOmega offers a scalable, sustainable solution,” he said.

“Our 33% stake, secured through strategic leadership rather than upfront capital, underlines the strength of LTR’s expertise and market position.

“This partnership allows us to capture upside in the rapidly growing omega-3 market without diluting resources needed for our core therapeutic pipeline.”

This article was developed in collaboration with LTR Pharma, a Stockhead advertiser at the time of publishing.  

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.